From the article you linked bub:
-
Therefore, the current literature data are controversial, and it is not yet possible to establish a causal relationship between 5α-reductase inhibitors and the persistence of sexual symptoms. The studies that demonstrated a higher incidence of persistent side effects related to the use of finasteride have important biases and included limited samples, and are insufficient to confirm the existence of PFS. Likewise, they also do not allow distinguishing between a real adverse effect or a nocebo reaction to the medication. This nocebo effect was well documented in a study comparing patients who received counseling prior to finasteride treatment regarding the possibility of sexual side effects and those who had not; 43.6% of the patients who were informed presented symptoms, compared with 15.3% of the other group.14 The nocebo effect may also be related to the occurrence of persistent sexual complaints.
At best you could potentially make an argument that finasteride can have permanent effects in rodents. Rodents who are not human beings and were also taking huge doses of fin and Dut.
Further as I’ve said before, most people it’s “PFS” are mentally ill, again from the article you posted:
-
Following this same idea, in 2018, a study included 97 men aged 18 years or older who reported persistent adverse effects after using finasteride at a daily dose of 1 mg for at least three months, excluding those with basic sexual dysfunction and non-confirmed psychiatric diagnosis.33 Of the participants, 55% had had a psychiatric diagnosis prior to the use of finasteride and 28.8% had a history of psychiatric diagnosis in a first-degree relative; 11.3% had both. After discontinuing the drug, 34% reported anxiety and 49.3% depression; in 79.2% of those with depression, the condition was classified as moderate to severe, and in 10.4%, as severe.33 The researchers also reinforced the need for screening for a previous psychiatric history and counseling on the potential psychological consequences of using finasteride in predisposed individuals, weighing the risks and benefits of treatment.
And finally “But my NEUROSTEROIDS!”
